[Ip-health] Letter from KEI, Public Citizen, Oxfam America and HealthGap to Senator Hatch, regarding Colombia Compulsory License
claire.cassedy at keionline.org
Thu May 19 09:15:25 PDT 2016
Letter from KEI, Public Citizen, Oxfam America and HealthGap to Senator
Hatch, regarding Colombia Compulsory License
Attached is a letter that KEI, Public Citizen, Oxfam America and HealthGap
have sent to Senator Hatch, via the Senate Finance Committee, objecting to
the pressure his office has put on Colombia over a compulsory license on
patents held by Novartis for the cancer drug GLeevec. This refers to the
accounts of pressure from Hatch's office that are described in two letters
from the Colombia Embassy in Washington, dated April 27 and April 28, which
were recently leaked.
Among other things, the NGO letter to Hatch says:
"If these letters sent by the Embassy of Colombia are accurate, this is
a highly inappropriate and wholly objectionable attempt to interfere with
the right of the Colombian government to proceed with this compulsory
license through threats and distortions. In our view it is particularly
unconscionable that this be tied in any way to funding for Paz Colombia to
support the peace process."
We have a document with some context and background on the Colombia dispute
here: http://keionline.org/node/2568, and more generally here:
http://keionline.org/colombia. KEI has copies and English translations of
both letters. Public Citizen has more here on the history of the dispute:
For the groups signing this letter, the persons following this dispute
include James Love and Andrew Goldman from KEI, Rob Weissman, Peter
Maybarduk and Steve Steven Knievel from Public Citizen, Stephanie Burgos
from Oxfam America and Brook Baker from Health Gap.
There are NGOs in Colombia following this too, and some contacts include:
Francisco Rossi, Andrea Carolina Reyes Rojas, Luz Mariana Umbasia Bernal
and German Holguín, with contact details on the KEI FAQ.
We have also been collecting press clips on this here:
More information about the Ip-health